// App-Quantinova.ai

TPS3110 : Phase 1 study to evaluate the safety and tolerability of the CD40 agonistic monoclonal antibody APX005M in subjects with solid tumors.

Researchers

Presenter

  • Johanna C. Bendell

Principal Investigators

  • Marwan Fakih

  • Jeffrey R. Infante

  • David Lawrence Bajor

  • Mihaela C. Cristea

  • Thomas Tremblay

  • Ovidiu C. Trifan

  • Robert H. Vonderheide

Medical Centers

  • Sarah Cannon Research Institute/Tennessee Oncology, PLLC, Nashville, TN

  • City of Hope, Duarte, CA

  • Sarah Cannon Research Institute, Nashville, TN

  • University of Pennsylvania, Philadelphia, PA

  • Apexigen, San Carlos, CA

Locations

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Solid malignancies

Biomarkers

  • Cluster of Differentiation 40

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • Pharmacokinetics

  • Pharmacodynamics

  • Open Label

  • Multicenteric

  • Dose Escalation

  • First-In-Human

Phase

  • I

Study Id's

  • NCT02482168

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved